参蒲颗粒 | China Drugs ListShenpu Granules | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

企业
江苏康缘药业股份有限公司Jiangsu Kanion Pharmaceutical Co., Ltd.
药品类型
中成药Traditional Chinese medicine
治疗领域
泌尿与生殖健康Urology & reproductive health
公开来源记录的适应症
益气活血,清利湿热,通络止痛。用于盆腔炎性疾病后遗症引起的慢性盆腔痛中医辨证属湿热瘀阻证,症见下腹隐痛、腰骶胀痛、白带量多色黄、经行腹痛加重、胸闷纳呆、口干等,舌体胖大,色红,苔黄腻,脉弦数或滑数。TCM actions: replenishes qi, promotes blood circulation, clears damp-heat, unblocks the channels and relieves pain. For chronic pelvic pain caused by sequelae of pelvic inflammatory disease with the TCM pattern of damp-heat and blood-stasis obstruction. Symptoms include dull lower abdominal pain, distending lumbosacral pain, copious yellow vaginal discharge, worsening abdominal pain during menstruation, chest tightness, poor appetite and dry mouth; a swollen red tongue with a greasy yellow coating, and a wiry, rapid or slippery, rapid pulse.
适应症来源与口径
来源日期: 2026. 适应症反映所引用的历史批准范围,不是截至2026年的完整适应症。Source date(s): 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
说明书信息局限
尚未取得可核实的完整药品说明书。现有批准记录或国家医保局申报资料支持所示适应症;最新完整范围尚待确认。A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
中国可获得性状态
已核实中国历史批准记录;尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
海外状态
待逐一核查各市场。Market-by-market verification pending.
医保分类
2025国家医保目录未匹配;待人工复核Not matched in the 2025 national list; manual review pending
医保版本
2025版;2026年1月1日起执行2025 edition; effective 1 January 2026
医保核查说明
未在提取的目录中匹配到,并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

来源

打开交互详情、公开价格与讨论